Niacin Bone Regeneration Composition for Inflammatory Bone Loss

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for inflammatory bone resorption diseases such as periodontitis and rheumatoid arthritis, including surgical and chemotherapeutic methods, fail to effectively regenerate deficient or resorbed alveolar bone, and existing compounds like niacin are not proven to have bone regeneration effects beyond promoting blood circulation.

Innovation Solution

A bone regeneration agent containing niacin or nicotinate as an active ingredient, which is administered topically or orally, promotes bone regeneration in deficient or resorbed areas through direct application to the gums or periodontal tissue.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If growth factors are used to promote bone regeneration, then bone formation is enhanced, but production costs become excessively high and handling becomes difficult

Engineering Contradiction:

Improvebone regeneration efficacyVSAvoidproduction cost and handling

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent uses bone morphogenetic protein subunits (intermediaries) that can be easily produced and handled, which then assemble to form the active bone morphogenetic protein complex. This mediator approach allows bone regeneration without directly using the complex, expensive full-length growth factor, thus resolving the contradiction between efficacy and manufacturability

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The bone morphogenetic protein is divided into smaller subunits (e.g., N-terminal and C-terminal domains) that can be independently produced, purified, and stored. These segmented components are then combined to form the active complex, making the overall system more manageable and cost-effective while maintaining bone regeneration functionality

Inventive Principle:

Principle #1Segmentation

2Quantity of substance

If organic solvents are used to dissolve hydrophobic bone morphogenetic proteins, then solubility is improved, but safety concerns arise from residual solvents

Engineering Contradiction:

Improvesolubility of bone morphogenetic proteinVSAvoidsafety from residual solvents

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent changes the molecular parameters of the bone morphogenetic protein by modifying its sequence (e.g., reducing hydrophobicity, adding solubility-enhancing sequences) or using different isoforms that are inherently more soluble. This parameter change allows the protein to dissolve in safe, physiologically compatible solutions without requiring organic solvents

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses recombinant DNA technology to create copies of the bone morphogenetic protein with modified sequences that enhance solubility. These engineered copies maintain the biological activity needed for bone regeneration while being soluble in safe aqueous solutions, eliminating the need for organic solvents

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The niacin-based agent significantly regenerates deficient or resorbed bone in inflammatory bone resorption diseases, offering a pharmaceutical, cosmetic, or food-based solution for treating conditions like periodontitis and rheumatoid arthritis.

Implementation Method 1

a collagen scaffold having a fibrous network structure

Methodology Applied

Scientific EffectFibrous network structure:

Implementation Method 2

a bone morphogenetic protein complex having a bone inducing capability

Methodology Applied

Scientific EffectBone morphogenetic protein signaling:

Data Source

PatentEP3632435B1Bone regeneration agent

Publication Date: 2026.04.29 KAO CORP

Figure 1
Figure 2(A)~2(D)

AI summary

A bone regeneration agent for regenerating a deficient or resorbed bone due to an inflammatory bone resorption disease, containing a niacin compound as an active ingredient.